- Home
- GME vs ABVX Comparison
GME vs ABVX Comparison
Compare GME & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GME
- ABVX
- Stock Information
- Founded
- GME 1996
- ABVX 2013
- Country
- GME United States
- ABVX France
- Employees
- GME N/A
- ABVX N/A
- Industry
- GME Electronics Distribution
- ABVX
- Sector
- GME Consumer Discretionary
- ABVX
- Exchange
- GME Nasdaq
- ABVX Nasdaq
- Market Cap
- GME 11.8B
- ABVX 9.6B
- IPO Year
- GME 2002
- ABVX N/A
- Fundamental
- Price
- GME $20.07
- ABVX $118.88
- Analyst Decision
- GME Sell
- ABVX Buy
- Analyst Count
- GME 1
- ABVX 11
- Target Price
- GME $13.50
- ABVX $110.36
- AVG Volume (30 Days)
- GME 5.6M
- ABVX 1.4M
- Earning Date
- GME 12-09-2025
- ABVX 08-11-2025
- Dividend Yield
- GME N/A
- ABVX N/A
- EPS Growth
- GME 481.76
- ABVX N/A
- EPS
- GME 0.76
- ABVX N/A
- Revenue
- GME $3,847,500,000.00
- ABVX $7,073,400.00
- Revenue This Year
- GME $9.86
- ABVX $6.80
- Revenue Next Year
- GME $2.83
- ABVX N/A
- P/E Ratio
- GME $26.54
- ABVX N/A
- Revenue Growth
- GME N/A
- ABVX N/A
- 52 Week Low
- GME $19.93
- ABVX $4.77
- 52 Week High
- GME $35.81
- ABVX $126.99
- Technical
- Relative Strength Index (RSI)
- GME 22.66
- ABVX 68.49
- Support Level
- GME $21.23
- ABVX $110.25
- Resistance Level
- GME $20.69
- ABVX $126.99
- Average True Range (ATR)
- GME 0.56
- ABVX 6.26
- MACD
- GME -0.09
- ABVX 1.15
- Stochastic Oscillator
- GME 3.54
- ABVX 73.26
About GME GameStop Corporation
GameStop Corp is a U.S. multichannel video game, consumer electronics, and services retailer. The company operates across Europe, Canada, Australia, and the United States. The company sells new and second-hand video game hardware, physical and digital video game software, and video game accessories, mainly through GameStop, EB Games, and Micromania stores and international e-commerce sites. The majority of sales are from the United States. The company categorizes its products in three categories: Hardware and accessories, Software, and Collectibles. The company generates the majority of its revenue from the sale of Hardware and accessories products.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.